Recently, Juncell Therapeutics has completed Series A+ and A++ funding at a level of nearly ¥ 150 million, jointly invested by Huaige Capital, ALAN AMC, Huangpu Medical Fund, bioVENTURE and HY Capital, followed by existing shareholders KAITAI Capital and Oriza Seed, and with Haoyue Capital as the exclusive financial adviser.

Dr. Huajun Jin, founder of Juncell Therapeutics, said: TIL therapies have great potential for the treatment of solid tumors, however, there is a great challenge to develop highly personalized TIL therapies. To this end, we have systematically optimized the cell culture process and independently established a quality management system according to the GMP specification, achieving international advanced level in terms of culture success rate, cell count, cytotoxic activity and other indicators. Clinically, even without intensive lymphodepletion and IL-2 injection, our TIL therapy has demonstrated great efficacy in several patients with advanced solid tumors of different types. The safety was also enhanced since the patients receive treatment just in general wards. It is a great honor to win the favor of the well-known funds including Huaige Capital, ALAN AMC, Huangpu Medical Fund, bioVENTURE and HY Capital, etc., and sincere gratitude to our existing shareholders KAITAI Capital and Oriza Seed for their further support, as well as Haoyue Capital for the consistent professional assistance! We will focus on the TIL field and accelerate the clinical development of various TIL therapies in different TIL pipelines.